Absence of transforming growth factor-β type II receptor is associated with poorer prognosis in HER2-negative breast tumours

Annals of Oncology

Volumn 21, Issue 4, 2009, Pages 734-740

  Paiva, C E ^a   Drigo, S A ^a   Rosa, F E ^a   Moraes Neto, F A ^b   Caldeira, J R F ^b   Soares, F A ^c   Domingues, M A C ^a   Rogatto, S R ^a  

^a SÃO PAULO STATE UNIVERSITY UNESP   (Brazil)

^b Amaral Carvalho Hospital   (Brazil)

^c A C Camargo Cancer Treatment and Research Center   (Brazil)

Author keywords

Breast cancer; HER2; Prognostic markers; TGF 1; TGF RII

Indexed keywords

ANTINEOPLASTIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR 2; TRANSFORMING GROWTH FACTOR BETA RECEPTOR 2; TRANSFORMING GROWTH FACTOR BETA2;

ADJUVANT THERAPY; ADULT; ARTICLE; BREAST CARCINOMA; BREAST SURGERY; CANCER SURVIVAL; CARCINOMA CELL; CONTROLLED STUDY; DISEASE FREE SURVIVAL; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; METASTASIS; METASTASIS POTENTIAL; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; PROTEIN DETERMINATION; PROTEIN EXPRESSION;

ADULT; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; CARCINOMA; DOWN-REGULATION; FEMALE; FOLLOW-UP STUDIES; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, ERBB-2; HUMANS; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROTEIN-SERINE-THREONINE KINASES; RECEPTORS, TRANSFORMING GROWTH FACTOR BETA; SURVIVAL ANALYSIS; TRANSFORMING GROWTH FACTOR BETA1; TUMOR MARKERS, BIOLOGICAL; YOUNG ADULT;

EID: 77951966115     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdp518     Document Type: Article

References (27)

1. Sotiriou C, Piccart MJ. Taking gene-expression profiling to the clinic: when will molecular signatures become relevant to patient care? Nat Rev Cancer 2007; 7: 545-553.
2. Tan AR, Alexe G, Reiss M. Transforming growth factor-beta signaling: emerging stem cell target in metastatic breast cancer? Breast Cancer Res Treat 2009; 115: 453-495.
3. Massague J. TGFbeta in cancer. Cell 2008; 134: 215-230.
4. Gobbi H, Dupont WD, Simpson JF et al. Transforming growth factor-beta and breast cancer risk in women with mammary epithelial hyperplasia. J Natl Cancer Inst 1999; 91: 2096-2101.
5. Leivonen SK, Kahari VM. Transforming growth factor-beta signaling in cancer invasion and metastasis. Int J Cancer 2007; 121: 2119-2124.
6. Muraoka RS, Koh Y, Roebuck LR et al. Increased malignancy of Neu-induced mammary tumors overexpressing active transforming growth factor beta1. Mol Cell Biol 2003; 23: 8691-8703.
7. Wilson CA, Cajulis EE, Green JL et al. HER-2 overexpression differentially alters transforming growth factor-beta responses in luminal versus mesenchymal human breast cancer cells. Breast Cancer Res 2005; 7: R1058-R1079.
8. Marrogi AJ, Munshi A, Merogi AJ et al. Study of tumor infiltrating lymphocytes and transforming growth factor-beta as prognostic factors in breast carcinoma. Int J Cancer 1997; 74: 492-501.
9. Koumoundourou D, Kassimatis T, Zolota V et al. Prognostic significance of TGFbeta-1 and pSmad2/3 in breast cancer patients with T1-2,N0 tumours. Anticancer Res 2007; 27: 2613-2620.
10. Gorsch SM, Memoli VA, Stukel TA et al. Immunohistochemical staining for transforming growth factor beta 1 associates with disease progression in human breast cancer. Cancer Res 1992; 52: 6949-6952.
11. Desruisseau S, Palmari J, Giusti C et al. Determination of TGFbeta1 protein level in human primary breast cancers and its relationship with survival. Br J Cancer 2006; 94: 239-246.
12. Rosa FE, Caldeira JR, Felipes J et al. Evaluation of estrogen receptor alpha and beta and progesterone receptor expression and correlation with clinicopathologic factors and proliferative marker Ki-67 in breast cancers. Hum Pathol 2008; 39: 720-730.
13. Rosa FE, Silveira SM, Silveira CG et al. Quantitative real-time RT-PCR and chromogenic in situ hybridization: precise methods to detect HER-2 status in breast carcinoma. BMC Cancer 2009; 9: 90.
14. Pfaffl MW. A new mathematical model for relative quantification in real-time RTPCR. Nucleic Acids Res 2001; 29: e45.
15. Nagai MA, Fregnani JH, Netto MM et al. Down-regulation of PHLDA1 gene expression is associated with breast cancer progression. Breast Cancer Res Treat 2007; 106: 49-56.
16. Bierie B, Moses HL. Tumour microenvironment: TGFbeta: the molecular Jekyll and Hyde of cancer. Nat Rev Cancer 2006; 6: 506-520.
17. Hinshelwood RA, Huschtscha LI, Melki J et al. Concordant epigenetic silencing of transforming growth factor-beta signaling pathway genes occurs early in breast carcinogenesis. Cancer Res 2007; 67: 11517-11527.
18. Gobbi H, Arteaga CL, Jensen RA et al. Loss of expression of transforming growth factor beta type II receptor correlates with high tumour grade in human breast in-situ and invasive carcinomas. Histopathology 2000; 36: 168-177.
19. Mizukami Y, Nonomura A, Yamada T et al. Immunohistochemical demonstration of growth factors, TGF-alpha, TGF-beta, IGF-I and neu oncogene product in benign and malignant human breast tissues. Anticancer Res 1990; 10: 1115-1126.
20. Buck MB, Pfizenmaier K, Knabbe C. Antiestrogens induce growth inhibition by sequential activation of p38 mitogen-activated protein kinase and transforming growth factor-beta pathways in human breast cancer cells. Mol Endocrinol 2004; 18: 1643-1657.
21. Buck MB, Fritz P, Dippon J et al. Prognostic significance of transforming growth factor beta receptor II in estrogen receptor-negative breast cancer patients. Clin Cancer Res 2004; 10: 491-498.
22. Schneider BP, Winer EP, Foulkes WD et al. Triple-negative breast cancer: risk factors to potential targets. Clin Cancer Res 2008; 14: 8010-8018.
23. Ueda Y, Wang S, Dumont N et al. Overexpression of HER2 (erbB2) in human breast epithelial cells unmasks transforming growth factor beta-induced cell motility. J Biol Chem 2004; 279: 24505-24513.
24. Seton-Rogers SE, Lu Y, Hines LM et al. Cooperation of the ErbB2 receptor and transforming growth factor beta in induction of migration and invasion in mammary epithelial cells. Proc Natl Acad Sci USA 2004; 101: 1257-1262.
25. Forrester E, Chytil A, Bierie B et al. Effect of conditional knockout of the type II TGF-beta receptor gene in mammary epithelia on mammary gland development and polyomavirus middle T antigen induced tumor formation and metastasis. Cancer Res 2005; 65: 2296-2302.
26. Yang L, Huang J, Ren X et al. Abrogation of TGF beta signaling in mammary carcinomas recruits Gr-1+CD11b+ myeloid cells that promote metastasis. Cancer Cell 2008; 13: 23-35.
27. Olopade OI, Grushko TA, Nanda R, Huo D. Advances in breast cancer: pathways to personalized medicine. Clin Cancer Res 2008; 14: 7988-7999.